Glenmark Life Sciences IPO - Grey Market, GMP & Reviews

IPO Details

Issue Date 27 Jul 2021 - 29 Jul 2021
Issue Size ₹1513.6 Cr
Issue Price ₹695-720
Market Lot 20 Shares
Shares on Offer
Registrar KFintech
GMP ₹145-150
Kostak ₹350
Subject to Sauda ₹1600
Listing Date 06 Aug 2021
Listing Price ₹751.10
Listing Gain% 4.17

About Glenmark Life Sciences Limited

They are in the business of making high-quality drugs by unlocking the possibilities of science. Over the years, we have established strong relationships with leading global generic pharmaceutical companies that have helped us expand their product offerings and geographic reach. They work with 16 of the 20 largest generic companies globally.

Their Company is promoted by Chintan Shah, Ajay Patel and Shekhar Somani, who each have over 24 years in the specialty chemicals manufacturing industry and have established strong business relationships with domestic as well as overseas customers. In addition, they are led by a well – qualified and experienced management team, which they believe has demonstrated its ability to manage and grow their operations and has substantial experience in the sectors in which they operate. They believe that the knowledge and experience of their management team provides us with a significant competitive advantage as they seek to grow their business.

Company Promoters

Glenmark Pharmaceuticals Limited is the promoter of the company.

Company Financials

Particulars 31-Mar-21 31-Mar-20 31-Mar-19
Total Assets (In ₹ Millions) 19,970.75 17,256.04 14,753.95
Total Revenue (In ₹ Millions) 18,859.76 15,493.03 8,868.65
Profit After Tax (PAT) (In ₹ Millions) 3,515.81 3,130.98 1,955.92

Grey Market Premium Updates

Date GMP Kostak Subject to Sauda
30 Jul 2021 ₹145-150 ₹350 ₹1600
29 Jul 2021 ₹115-117 ₹250-300 ₹1200-1400
28 Jul 2021 ₹114-115 N/A N/A
24 Jul 2021 ₹190-200 ₹350 ₹2400-2600
21 Jul 2021 N/A ₹400 N/A

Strengths & Weaknesses

Strength
Weakness

Glenmark Life Sciences Limited IPO Reviews

  • Rating: 
  • Recommendation:

Subscription Details

Date & Time QIB NII RII Total
Day 1 - 27 Jul 2021 0.00 0.86 5.17 2.78
Day 2 - 28 Jul 2021 1.38 3.39 9.28 5.78
Day 3 - 29 Jul 2021 36.97 122.54 14.63 44.17

Allotment Status

Please click the link below to check the IPO allotment status.

IPO Allotment Status

Glenmark Life Sciences Limited IPO FAQs

  1. When will Glenmark Life Sciences Limited IPO open?

    Glenmark Life Sciences Limited IPO will open on 27 Jul 2021 and close on 29 Jul 2021.

  2. What is the listing date of Glenmark Life Sciences Limited IPO?

    Glenmark Life Sciences Limited IPO will list on 06 Aug 2021.

  3. What is the offer price of Glenmark Life Sciences Limited IPO?

    The offer price of Glenmark Life Sciences Limited IPO is ₹695-720.

  4. What is the lot size of Glenmark Life Sciences Limited IPO?

    The lot size of Glenmark Life Sciences Limited IPO is 20.

  5. What is the Grey Market Premium (GMP) price of Glenmark Life Sciences Limited IPO?

    The Grey Market Premium (GMP) price of Glenmark Life Sciences Limited IPO is ₹145-150.

  6. What is the Kostak price of Glenmark Life Sciences Limited IPO?

    The Kostak price of Glenmark Life Sciences Limited IPO is ₹350.

  7. What is the Subject to Sauda price for Glenmark Life Sciences Limited IPO?

    The Subject to Sauda price for Glenmark Life Sciences Limited IPO is ₹1600.

Glenmark Life Sciences Limited IPO Review/Comments

The IPO of API manufacturer Glenmark Life Sciences is scheduled to hit the markets on July 27th, marking this year’s 29th public offering. The company was spun off as a wholly-owned API business subsidiary of Glenmark Pharmaceuticals in 2018. Even though it has been doing some good business owing to rising market and policy winds favouring generics and patent liberation, this IPO may not have come at a particularly good time, in light of Glenmark Life’s financial obligation to its parent. Read more on why this IPO may or may not be a good buy by clicking on the link below. https://transfin.in/glenmark-life-sciences-ipo-why-it-may-not-be-the-best-buy

Glenmark Life Sciences IPO

Guest User

Please Leave Your Message